Literature DB >> 8873360

Childhood urolithiasis: urological management of upper tract calculi in the era of extracorporeal shock-wave lithotripsy.

M Robert1, N Drianno, J Guiter, M Averous, D Grasset.   

Abstract

OBJECTIVE: To evaluate the management of urolithiasis in children since the development of extracorporeal shock-wave lithotripsy (ESWL).
METHODS: Between 1988 and 1994, 37 children, aged from 2 to 15 years (mean 10), with upper tract urolithiasis were evaluated and treated. Lithogenic metabolic disorders or anomalies of the urinary tract were present in 11 children (30%) Urolithiasis was multiple in 9 cases and bilateral in 2 cases. A total of 47 renal (30) or ureteral (17) stones were managed, of which 5 were partial or complete staghorn calculi. Initial treatment was surgery in 4 cases (1 nephrectomy, partial nephrectomy and 2 pyelolithotomies) and piezoelectric ESWL in 43 cases.
RESULTS: The overall ESWL success rate was 82.2%, with auxillary endoscopic procedures in 3 cases. ESWL failures required surgical stone removal in 5 cases, endoscopic ureterolithotripsy in 1 case and electrohydraulic ESWL in 1 case. Residual fragments after pyelolithotomies were also treated by ESWL.
CONCLUSION: ESWL is the mainstay of treatment of childhood upper tract urolithiasis, but other therapeutic methods retain specific indications. Its application requires great vigilance and its long-term effects are uncertain. It is therefore important to rule out any underlying pathology and where possible to prevent further stone formation.

Entities:  

Mesh:

Year:  1996        PMID: 8873360     DOI: 10.1159/000282882

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  Combined treatment of immobilization staghorn stones in 14-year old boy.

Authors:  A Slavković; M Vlajković; M Radovanović; Z Sirić; V Stefanović
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 2.  [Urolithiasis in childhood].

Authors:  T Knoll; U Humke
Journal:  Urologe A       Date:  2013-08       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.